Jacobs M R, Bajaksouzian S
Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Diagn Microbiol Infect Dis. 1997 Jul;28(3):105-12. doi: 10.1016/s0732-8893(97)00008-4.
A 1994 to 1995 national Haemophilus influenzae surveillance study of 1910 strains showed that 13 strains (0.7%) were resistant to amoxicillin/clavulanic acid (MIC, > or = 8/4 micrograms/ml). These and other selected strains were investigated further in this study. Susceptibility of the surveillance study strains was determined with the commercial microdilution trays used in the original study and in triplicate with reference broth microdilution trays prepared by the investigators, as well as by Etest and disk diffusion. Amoxicillin/clavulanic acid resistance was confirmed for only one of the surveillance study strains. This strain produced double zones of growth with Etest and disk-diffusion methods, with the double zone containing spheroplasts. When the amoxicillin/clavulanic acid MICs of all beta-lactamase positive strains were compared, MIC results obtained with surveillance study trays and the Etest were one to two dilutions higher than MICs obtained with reference trays. The distribution and modal amoxicillin/clavulanic acid MICs of beta-lactamase-positive and -negative strains was essentially the same for a comparison group of strains using reference trays, in contrast to a fourfold higher modal MIC for beta-lactamase-positive strains using surveillance study reagents and strains. These differences in MICs could be attributed to variations in inoculum, the presence of spheroplasts, and/or a difference in potency of amoxicillin and/or clavulanic acid in the tray and Etest reagents used. Methods for assessing the adequacy of the clavulanic acid content are not adequate, amoxicillin control values and a beta-lactamase-positive H. influenzae control strain are required.
1994年至1995年对1910株流感嗜血杆菌进行的一项全国性监测研究表明,有13株(0.7%)对阿莫西林/克拉维酸耐药(MIC,≥8/4微克/毫升)。本研究对这些菌株和其他选定菌株进行了进一步调查。监测研究菌株的药敏性通过原研究中使用的商业微量稀释板进行测定,并与研究人员制备的参考肉汤微量稀释板一式三份进行测定,同时也通过Etest和纸片扩散法进行测定。仅对监测研究中的一株菌株确认了阿莫西林/克拉维酸耐药。该菌株在Etest和纸片扩散法中产生了双生长带,双生长带中含有原生质球。当比较所有β-内酰胺酶阳性菌株的阿莫西林/克拉维酸MIC时,监测研究板和Etest获得的MIC结果比参考板获得的MIC高1至2个稀释度。对于使用参考板的一组菌株,β-内酰胺酶阳性和阴性菌株的阿莫西林/克拉维酸MIC分布和众数基本相同,而使用监测研究试剂和菌株时,β-内酰胺酶阳性菌株的众数MIC高四倍。这些MIC的差异可能归因于接种量的变化、原生质球的存在和/或所用平板和Etest试剂中阿莫西林和/或克拉维酸效力的差异。评估克拉维酸含量是否充足的方法并不充分,需要阿莫西林对照值和β-内酰胺酶阳性流感嗜血杆菌对照菌株。